Abstract 1853P
Background
Frankl's Logotherapy is a psychotherapeutic approach aimed at finding meaning in life. Although the incidence of death anxiety, existential loneliness, and depression in cancer patients is high, the efficacy of Logotherapy in this population is not well established.
Methods
Two independent investigators searched PubMed, Embase, and Cochrane Library databases up to March 2023. We systematically reviewed, according to PRISMA guidelines, controlled clinical trials evaluating the use of Logotherapy in cancer anxiety symptoms. We performed a pooled analysis on anxiety scores of patients that underwent group Logotherapy sessions vs. non-exposed control groups.
Results
We included seven studies, four randomized controlled trials (RCTs), and three quasi-experimental, comprising 280 patients, published between 1977 and 2023. A total of 139 patients (49.6%) had sessions of Logotherapy, and ages ranged from 18 to more than 68 years. Total treatment duration ranged between 360 and 1200 minutes. The Standard Mean Difference (SMD) for anxiety symptoms was -1.63 (95% CI = [-2.65, -0.61]; z = 3.12; P = 0.002; I2 = 92%) in patients who underwent Logotherapy compared to non-exposed control groups. In a subgroup analysis including only RCTs, a similar effect was observed with an SMD of -0.64 (95% CI = [-1.72, 0.44]; z = 1.16; P = 0.25; I2 = 91%).
Conclusions
Despite limited evidence, Logotherapy group sessions were associated with a reduction in anxiety scores of adult patients with cancer when compared to inactive control groups.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
A.V. Teixeira Filho.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1999P - IMreal Cohort 4: Third interim analysis of efficacy and safety in patients (pts) with extensive-stage small cell lung cancer (ES-SCLC) receiving atezolizumab plus carboplatin and etoposide (atezo + CE) as first-line (1L) therapy under real-world conditions (RWCs)
Presenter: Sanjay Popat
Session: Poster session 05
2000P - Efficacy and safety of thoracic radiotherapy after first-line immunotherapy in extensive stage small cell lung cancer: A multi-center retrospective study
Presenter: Jiake Wu
Session: Poster session 05
2001P - Consolidative thoracic radiotherapy of extensive-stage small cell lung cancer in the era of chemoimmunotherapy: A retrospective analysis concerning patients from southern Italy
Presenter: Vito Longo
Session: Poster session 05
2002P - A multicentre study assessing the real-world effectiveness of first-line chemotherapy plus immunotherapy in extensive-stage small cell lung cancer (ES-SCLC) patients
Presenter: Marie Porte
Session: Poster session 05
2003P - Consolidative intrathoracic radiotherapy during maintenance first-line immunotherapy in extensive stage small cell lung cancer (ES-SCLC): A retrospective multicenter analysis of safety and efficacy
Presenter: Alessio Bruni
Session: Poster session 05
2004P - PD-L1 Inhibitors combined with whole brain radiotherapy in patients with small cell lung cancer brain metastases: Real-world evidence
Presenter: Litang Huang
Session: Poster session 05
2005P - Anlotinib combined with chemotherapy in the treatment of first-line extensive-stage small cell lung cancer (ES-SCLC): A real-world study
Presenter: Fangfang Gao
Session: Poster session 05
2006P - Immune activation effect and survival of different irradiated sites in ES-SCLC patients treated with radioimmunotherapy: A real-world analysis
Presenter: Min Wu
Session: Poster session 05
2007P - Real-world (rw) outcomes to chemoimmunotherapy and biomarker analysis in extensive-stage small cell lung cancer (ES SCLC)
Presenter: Emmanouil Panagiotou
Session: Poster session 05